

JUL 20 2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Walke et al.

Application No.: 09/755,016

Filed: January 5, 2001

Group Art Unit: 2821

Title: Novel Human Proteases and
Polynucleotides Encoding the Same

Examiner: To Be Assigned

Attorney Docket No.: LEX-0114-USA

TECH CENTER 1600 22900

OCT 05 2001

RECEIVED

Assistant Commissioner for Patents

Washington, D.C. 20231

Box DD

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.97(b), or

(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)

under 37 CFR 1.97(c) together with either a:

Certification under 37 CFR 1.97(e), or

a \$240.00 fee under 37 CFR 1.17(p), or

(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with a:

Certification under 37 CFR 1.97(e), and

a petition under 37 CFR 1.97(d)(2)(ii) ...¹

1. See 37 CFR 1.97(d)(2)(ii).

Appointee(s) submit herewith Form PTO-1449-Information Disclosure Citation together with

copies of the cited documents, and a copy of the Information Disclosure Statement.

believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.



07/17/01
Date

Respectfully submitted,

Lance K. Ishimoto

Reg. No. 41,866

LEXICON GENETICS INCORPORATED
4000 Research Forest Drive
The Woodlands, TX 77381
(281) 863-3333

OCT 9 5 2001

TECH CENTER 1500 2500

RECEIVED

